Phase Holographic Imaging logotype

Investor Relations

Welcome to the Investor Relations for Phase Holographic Imaging (PHI)

What’s New

Press Releases

The HoloMonitor HoloLids are specially designed to eliminate image disturbances, caused by surface vibrations and condensation inside the cell culture vessel.

Interim Report 4 2024/25

This spring has been a dynamic and productive period for PHI, as our team and partners have made significant efforts on multiple fronts. Externally, our collaboration with Altium has focused on expanding our sales processes and networks and enhancing our market presence. Internally, our dedicated team has been advancing our ongoing regenerative medicine projects and refining our HoloMonitor technology.
123…153

News featuring PHI

A hand holding a microphone against a dark background.

Biostock inverview with acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology. Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U.S. institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine. Biostock has interviewed the acting CEO, Ivan Jurković, to learn more.
123…40

About PHI

Phase Holographic Imaging (PHI) develops and markets its non-invasive time-lapse imaging instruments. The company’s current HoloMonitor® products are globally used for long-term quantitative analysis of living cell cultures, particularly in preclinical research.

Now, PHI is actively focusing on business development. With unique solutions focused on Quantitative Phase Imaging (QPI) — a technology that brings a novel, cell-friendly approach to critical cell quality evaluation, PHI is expanding into the fast-growing regenerative medicine field.

PHI envisions transforming live cell analysis and establishing its QPI technology as a standard for cell quality control, making our future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.

Learn more about PHI
Key Figures
Why invest in PHI?

July 2024 Interview with PHI AB — Step inside our headquarters and meet the team!

Finwire Media interviewed us about our current business and future outlook in regenerative medicine. How are we shaping the future of scientific research and cell therapy quality control with our innovative live cell analysis technology? How are we positioned to reach profitability, and why do investors take a closer look at PHI?

Investor Information

report banner investor relations

All Press Releases

Here you can read all PHI press releases.

Read Press Releases
A fluorescence equipped HoloMonitor system operating inside a cell incubator at Novo Nordisk A/S

Company News

Here you see PHI featured in news and CEO commentaries.

See Company News
graph banner

Reports & Documents

Here you find PHI’s interim and annual reports, as well as view general meeting and emission documents.

Find Reports & Documents
question banner investor relations phase holographic imaging

Investor Q&A

Here you can browse the frequently asked investor questions and quickly find your answers.

Browse Investor Q&A

Any questions? Please get in touch with our CEO,
Ivan Jurkovic, at: ir@phiab.com

Investor Calendar

Interim Report 3 2024/25

March 13, 2025

Stock Information

The PHI stock is listed on the Spotlight Stock Market,
a Multilateral Trading Facility (MTF).

PHI on Swedish Spotlight Market (PHI)

Since August 15th, 2024, PHI has also been dual-listed on the US-based OTCQB Venture Market.

PHI on US-OTCQB Market (OTCQB:PHIXF)

Subscribe to the latest PHI news from BioStock, Kalqyl and Cision to stay informed.
You are welcome to follow PHI on social media, where we keep in touch with our global HoloMonitor community.

Thank you to our investor community for sharing our vision, and believing in the company and the impact our products and technology have on advancing research within life science and the future of medicine.